• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Concept Life Sciences launches, acquires three companies in $100M deal

Concept Life Sciences launches, acquires three companies in $100M deal

July 14, 2014
CenterWatch Staff

Concept Life Sciences, a newly formed international scientific laboratory and consultancy business, has made three acquisitions with a combined enterprise value approaching $100 million, following backing from Equistone Partners Europe. Concept Life Sciences acquired Peakdale Molecular, Resource & Environmental Consultants (REC) and Scientific Analysis Laboratories (SAL), which operate a number of sites across the U.K. 

Headquartered in Manchester, the group currently is focused on laboratory-based analytical testing and complex chemistry synthesis, with a view to accelerate investment in biological sciences, cell-based ADME services, biostorage and stability testing. 

Executive Chairman Michael Fort and CEO Alan Morgan will lead the business, which has over 500 staff across 10 core locations. Equistone partner Steve O'Hare and investment director Andi Tomkinson both join the board as non-executive directors. 

O'Hare said, "We've worked closely with the management team to develop the new group, whilst simultaneously making the foundation acquisitions, which have given entry into high-growth markets. The company has established a strong presence nationally and created a platform to target international growth and expand its service offering to existing clients. We look forward to developing the business further through the execution of its buy-and-build strategy."

Morgan said, "The acquisitions are the first steps in building a comprehensive platform of services for our clients requiring science-based innovative solutions. Our objective is to expand our capacity across a broad range of services adjacent to our current capabilities in life, food and environmental sciences."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing